ArticleWorld journal of surgical oncology2012
Upregulated expression of annexin II is a prognostic marker for patients with gastric cancer.
Article in World journal of surgical oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Biomarkers of tumor invasiveness in proteomics (Review).International journal of oncology · 2020Pooled it
- Progastrin, annexin A2, and tumor-associated macrophages in gastric adenocarcinoma.Journal of pathology and translational medicine · 2026Article
- Review
- The value of ATAD3A as a potential biomarker for bladder cancer.Cancer medicine · 2023Article
- Diagnostic and Therapeutic Approaches for Glioblastoma and Neuroblastoma Cancers Using Chlorotoxin Nanoparticles.Cancers · 2023Review
- Curcuminoids as Modulators of EMT in Invasive Cancers: A Review of Molecular Targets With the Contribution of Malignant Mesothelioma Studies.Frontiers in pharmacology · 2022Review
- Annexin A2 and Kidney Diseases.Frontiers in cell and developmental biology · 2022Review
- Advances in cancer treatment: a new therapeutic target, Annexin A2.Journal of Cancer · 2021Review
- Defective membrane repair machinery impairs survival of invasive cancer cells.Scientific reports · 2020Article
- ANXA2 Silencing Inhibits Proliferation, Invasion, and Migration in Gastric Cancer Cells.Journal of oncology · 2019Article
- Identification of natural compounds targeting Annexin A2 with an anti-cancer effect.Protein & cell · 2018Article
- Calcium channel α2δ1 subunit as a novel biomarker for diagnosis of hepatocellular carcinoma.Cancer biology & medicine · 2018Article
- Identification and Comparison of Differentiation-Related Proteins in Hepatocellular Carcinoma Tissues by Proteomics.Technology in cancer research & treatment · 2017Article
- CEACAM6 is a prognostic biomarker and potential therapeutic target for gastric carcinoma.Oncotarget · 2017Article
- Annexin A2 as a biomarker for hepatocellular carcinoma in Egyptian patients.World journal of hepatology · 2017Article
- Article
- What gastric cancer proteomic studies show about gastric carcinogenesis?Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Nomogram Incorporating CD44v6 and Clinicopathological Factors to Predict Lymph Node Metastasis for Early Gastric Cancer.PloS one · 2016Article
- The Annexin a2 Promotes Development in Arthritis through Neovascularization by Amplification Hedgehog Pathway.PloS one · 2016Article
- Gastric cancer: The times they are a-changin'.World journal of gastrointestinal oncology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe role of annexin II in the development and progression of gastric cancer was explored.
methodsReal-time PCR was conducted to detect annexin II and S100A6 mRNA expression. Protein expressions of annexin II and S100A6 were also examined by immunohistochemistry in 436 clinicopathologically characterized gastric cancer cases.
resultsThe expression of annexin II and S100A6 mRNA differ significantly among gastric tumor tissue and matched non-cancerous gastric mucosa. Protein levels of annexin II and S100A6 were up-regulated in gastric cancer compared with adjacent non-cancerous tissues. High expression of annexin II correlated with age, location of tumor, size of tumor, differentiation, histological type, depth of invasion, vessel invasion, lymph node metastasis, distant metastasis and Tumor, Node, Metastasis (TNM) stage, and also with expression of S100A6. Further multivariate analysis suggested that expression of annexin II and S100A6 were independent prognostic indicators for gastric cancer. Cumulative five-year survival rates of patients with high expression of both annexin II and S100A6 was significantly lower than those with low expression of both.
conclusionExpression of annexin II in gastric cancer was significantly associated with depth of invasion, lymph node metastasis and distant metastasis, TNM stage, high S100A6 expression, and poor prognosis. Annexin II and S100A6 proteins could be useful prognostic marker to predict tumor progression and prognosis in gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.